Dr Reddy’s found to infringe arthritis drug patent
17-07-2017
Horizon accuses Actavis of infringing Vimovo patents
12-08-2016
Duncan_Andison / iStockphoto.com
The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo (naproxen/esomeprazole magnesium).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
US Court of Appeals for the Federal Circuit, Horizon Pharma, Nuvo Pharmaceuticals, Vimovo, patent invalidity, arthritis, generic competition
